

REPLACEMENT SHEET

2. Use according to claim 1, wherein in formula (I) R₁ is hydrogen or methyl
and/or R₂ is hydrogen or methyl and/or R₄ is hydroxy or R₃ and R₄ together are oxo
5 and/or R₅ and R₆ are methyl.
3. Use according to claim 1, wherein the compound of formula (I) is
trilostane, ketotrilostane or epostane.
- 10 4. Use according to any one of claims 1 to 3, wherein the angiotensin II related
disease is a cardiovascular disease.
5. Use according to any one of the previous claims, wherein the angiotensin II
related disease is congestive heart failure, post myocardial infarction,
15 cardiomyopathy, diabetes, renal failure, metabolic syndrome (Syndrome X) or
arrhythmia.
6. Use according to claim 4, wherein the cardiovascular disease is post
myocardial infarction.
- 20 7. Use according to any one of the preceding claims, wherein the medicament is
administered in an amount of from 0.5 to 4 mg/kg/day.
8. Use according to any one of claims 1 to 3, wherein the angiotensin II related
25 disease is a proliferative disease.
9. Use according to claim 8, wherein the proliferative disease is peripheral
arterial disease, cerebro vascular disease, cardiofibrosis, cardiac myopathy, diabetic
retinopathy, diabetic gangrene, diabetic nephropathy, scleroderma, aneurism, asthma
30 or atheroma.
10. Use according to claim 8 or claim 9, wherein the proliferative disease is
cardiofibrosis.

2. Use according to claim 1, wherein in formula (I) R_1 is hydrogen or methyl and/or R_2 is hydrogen or methyl and/or R_4 is hydroxy or R_3 and R_4 together are oxo and/or R_5 and R_6 are methyl.
- 5 3. Use according to claim 1, wherein the compound of formula (I) is trilostane, ketotrilostane or epostane.
4. Use according to any one of claims 1 to 3, wherein the angiotensin II related disease is a cardiovascular disease.
- 10 *any one of the previous claims* *angiotensin II related*
5. Use according to ~~claim 4~~, wherein the ~~cardiovascular~~ disease is congestive heart failure, post myocardial infarction, cardiomyopathy, diabetes, renal failure, metabolic syndrome (Syndrome X) or arrhythmia.
- 15 6. Use according to claim 4, wherein the cardiovascular disease is post myocardial infarction.
7. Use according to any one of the preceding claims, wherein the medicament is administered in an amount of from 0.5 to 4 mg/kg/day.
- 20 8. Use according to any one of claims 1 to 3, wherein the angiotensin II related disease is a proliferative disease.
9. Use according to claim 8, wherein the proliferative disease is peripheral
- 25 arterial disease, cerebro vascular disease, ~~atheroma~~ cardiofibrosis, cardiac myopathy, diabetic retinopathy, diabetic gangrene, diabetic neph^rropathy, scleroderma, aneurism, asthma or atheroma.
10. Use according to claim 8 or claim 9, wherein the proliferative disease is
- 30 cardiofibrosis.